Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Extracellular Vesicles in Tauopathies: Mechanisms and Applications

Nannuri V., Ababneh E., El Rayes S., Smith J., Sugaya K., Zhao J.

Narrative Review on Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Mol Sci (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41752133
PMCID
PMC12940260
DOI
10.3390/ijms27041998

Abstract (original English)

Extracellular vesicles (EVs) are nanoscale membrane-enclosed vesicles that mediate intercellular communication and participate in both physiological and pathological signaling processes. Recent studies underscore the critical roles of EVs in the propagation of tau pathology and the diagnostic and therapeutic aspects of tauopathies, a class of neurodegenerative diseases marked by the pathological accumulation of the protein tau, contributing to cognitive decline and neuronal loss. This review aims to explore the many roles of EVs in tauopathies, emphasizing their ability to carry and transmit misfolded tau, modulate immune responses through microglial interactions, and serve as carriers of disease-specific biomarkers. We describe current findings on extravesicular tau, miRNAs, and mRNAs as diagnostic indicators in Alzheimer's disease and related tauopathies and evaluate the therapeutic potential of both endogenous and engineered EVs for delivering therapeutic agents or neuroprotective cargo. Challenges such as isolation standardization, cargo loading efficiency, and biodistribution are also discussed, along with potential strategies to overcome them. Overall, the evidence emphasizes EVs as key players in the pathophysiology, diagnosis, and treatment of tauopathies, offering a strong and compelling platform for precision medicine and clinical applications in the future.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansAlzheimer DiseaseTauopathiestau ProteinsMicroRNAsBiomarkersExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research